These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34623329)

  • 41. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
    Metzeler KH; Bloomfield CD
    Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.
    Mill CP; Fiskus W; DiNardo CD; Qian Y; Raina K; Rajapakshe K; Perera D; Coarfa C; Kadia TM; Khoury JD; Saenz DT; Saenz DN; Illendula A; Takahashi K; Kornblau SM; Green MR; Futreal AP; Bushweller JH; Crews CM; Bhalla KN
    Blood; 2019 Jul; 134(1):59-73. PubMed ID: 31023702
    [TBL] [Abstract][Full Text] [Related]  

  • 43. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.
    Greif PA; Konstandin NP; Metzeler KH; Herold T; Pasalic Z; Ksienzyk B; Dufour A; Schneider F; Schneider S; Kakadia PM; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
    Haematologica; 2012 Dec; 97(12):1909-15. PubMed ID: 22689681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in germline predisposition to acute leukaemias and myeloid neoplasms.
    Klco JM; Mullighan CG
    Nat Rev Cancer; 2021 Feb; 21(2):122-137. PubMed ID: 33328584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of RUNX1 in hematological malignancies.
    Sood R; Kamikubo Y; Liu P
    Blood; 2017 Apr; 129(15):2070-2082. PubMed ID: 28179279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.
    Grossmann V; Haferlach C; Weissmann S; Roller A; Schindela S; Poetzinger F; Stadler K; Bellos F; Kern W; Haferlach T; Schnittger S; Kohlmann A
    Genes Chromosomes Cancer; 2013 Apr; 52(4):410-22. PubMed ID: 23341344
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Frequent coexistence of RAS mutations in RUNX1-mutated acute myeloid leukemia in Arab Asian children.
    Al-Kzayer LF; Sakashita K; Al-Jadiry MF; Al-Hadad SA; Uyen le TN; Liu T; Matsuda K; Abdulkadhim JM; Al-Shujairi TA; Matti ZI; Hasan JG; Al-Abdullah HM; Inoshita T; Kamata M; Sughayer MA; Madanat FF; Koike K
    Pediatr Blood Cancer; 2014 Nov; 61(11):1980-5. PubMed ID: 25066867
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
    Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
    J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
    Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia.
    Fernando TR; Contreras JR; Zampini M; Rodriguez-Malave NI; Alberti MO; Anguiano J; Tran TM; Palanichamy JK; Gajeton J; Ung NM; Aros CJ; Waters EV; Casero D; Basso G; Pigazzi M; Rao DS
    Mol Cancer; 2017 Jul; 16(1):126. PubMed ID: 28724437
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.
    Sakurai M; Kunimoto H; Watanabe N; Fukuchi Y; Yuasa S; Yamazaki S; Nishimura T; Sadahira K; Fukuda K; Okano H; Nakauchi H; Morita Y; Matsumura I; Kudo K; Ito E; Ebihara Y; Tsuji K; Harada Y; Harada H; Okamoto S; Nakajima H
    Leukemia; 2014 Dec; 28(12):2344-54. PubMed ID: 24732596
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pediatric B-lymphoblastic leukemia with RUNX1 amplification: clinicopathologic study of eight cases.
    Reichard KK; Kang H; Robinett S
    Mod Pathol; 2011 Dec; 24(12):1606-11. PubMed ID: 21822204
    [TBL] [Abstract][Full Text] [Related]  

  • 53. RUNX1 point mutations potentially identify a subset of early immature T-cell acute lymphoblastic leukaemia that may originate from differentiated T-cells.
    Mok MM; Du L; Wang CQ; Tergaonkar V; Liu TC; Yin Kham SK; Sanda T; Yeoh AE; Osato M
    Gene; 2014 Jul; 545(1):111-6. PubMed ID: 24792891
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Landscape of Secondary Genetic Rearrangements in Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia with t(12;21).
    Kaczmarska A; Derebas J; Pinkosz M; Niedźwiecki M; Lejman M
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766699
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RUNX1 Mutations Can Lead to Aberrant Expression of CD79a and PAX5 in Acute Myelogenous Leukemias: A Potential Diagnostic Pitfall.
    Menter T; Lundberg P; Wenzel F; Dirks J; Fernandez P; Friess D; Dirnhofer S; Tzankov A
    Pathobiology; 2019; 86(2-3):162-166. PubMed ID: 30396184
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications.
    Gonzales F; Barthélémy A; Peyrouze P; Fenwarth L; Preudhomme C; Duployez N; Cheok MH
    Expert Opin Ther Targets; 2021 Apr; 25(4):299-309. PubMed ID: 33906574
    [No Abstract]   [Full Text] [Related]  

  • 57. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
    Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
    J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
    Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
    Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants.
    Luo X; Feurstein S; Mohan S; Porter CC; Jackson SA; Keel S; Chicka M; Brown AL; Kesserwan C; Agarwal A; Luo M; Li Z; Ross JE; Baliakas P; Pineda-Alvarez D; DiNardo CD; Bertuch AA; Mehta N; Vulliamy T; Wang Y; Nichols KE; Malcovati L; Walsh MF; Rawlings LH; McWeeney SK; Soulier J; Raimbault A; Routbort MJ; Zhang L; Ryan G; Speck NA; Plon SE; Wu D; Godley LA
    Blood Adv; 2019 Oct; 3(20):2962-2979. PubMed ID: 31648317
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia.
    Ganly P; Walker LC; Morris CM
    Leuk Lymphoma; 2004 Jan; 45(1):1-10. PubMed ID: 15061191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.